Evidence map›Paper›PMID 36004332›Full record

ArticleFrontiers in cellular and infection microbiology2022

Phylogenetic analysis of the viral proteins VP4/VP7 of circulating human rotavirus strains in China from 2016 to 2019 and comparison of their antigenic epitopes with those of vaccine strains.

Tongyao Mao, Mengxuan Wang, Jindong Wang, Yalin Ma, Xiafei Liu, Mingwen Wang, Xiaoman Sun, Lili Li, Huiying Li, Qing Zhang and 2 more

Erratum issuedAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Tongyao MaoKey Laboratory for Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, National Health Commission of the People's Republic of China, Beijing, China.
Mengxuan WangKey Laboratory for Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, National Health Commission of the People's Republic of China, Beijing, China.
Jindong WangDepartment of Medical Microbiology, Weifang Medical University, Weifang, China.
Yalin MaKey Laboratory for Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, National Health Commission of the People's Republic of China, Beijing, China.
Xiafei LiuKey Laboratory for Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, National Health Commission of the People's Republic of China, Beijing, China.
Mingwen WangKey Laboratory for Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, National Health Commission of the People's Republic of China, Beijing, China.
Xiaoman SunKey Laboratory for Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, National Health Commission of the People's Republic of China, Beijing, China.
Lili LiKey Laboratory for Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, National Health Commission of the People's Republic of China, Beijing, China.
Huiying LiKey Laboratory for Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, National Health Commission of the People's Republic of China, Beijing, China.
Qing ZhangKey Laboratory for Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, National Health Commission of the People's Republic of China, Beijing, China.
Dandi LiKey Laboratory for Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, National Health Commission of the People's Republic of China, Beijing, China.
Zhaojun DuanKey Laboratory for Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, National Health Commission of the People's Republic of China, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Group A rotaviruses (RVAs) are the most common etiological agents of severe acute diarrhea among children under 5 years old worldwide. At present, two live-attenuated RVA vaccines, LLR (G10P[15]) and RotaTeq (G1-G4, G6 P[8], P[5]), have been introduced to mainland China. Although RVA vaccines can provide homotypic and partially heterotypic protection against several strains, it is necessary to explore the genetic and antigenic variations between circulating RVAs and vaccine strains. In this study, we sequenced viral protein VP7 and VP4 outer capsid proteins of 50 RVA strains circulating in China from 2016 to 2019. The VP7 and VP4 sequences of almost all strains showed high homology to those of previously reported human strains and vaccine strains of the same genotype. However, in the presumed antigenic epitopes of the VP7 and VP4, multiple amino acid variations were found, regardless of the G and P genotypes of these strains. Moreover, all circulating G3 RVA strains in China potentially possess an extra N-linked glycosylation site compared with the G3 strain of RotaTeq. The potential N-linked glycosylation site at residues 69-71 was found in all G9 strains in China but not in the G9 strain of the Rotavac or Rotasill vaccine. These variations in antigenic sites might result in the selection of strains that escape the RVA neutralizing-antibody pressure imposed by vaccines. Furthermore, the G4 and P[6] genotypes in this study showed high homology to those of porcine strains, indicating the transmission of G4 and P[6] genotypes from pigs to humans in China. More genetic surveillance with antigenic evaluation in prevalent RVAs is necessary for developing and implementing rotavirus vaccines in China.

Indexed as

Antigens, ViralRotavirusRotavirus InfectionsViral ProteinsAnimalsCapsid ProteinsChildChild, PreschoolChinDiarrheaEpitopesGenotypeHumansPhylogenySwineAntigens, ViralCapsid ProteinsEpitopesViral Proteinsantigenic epitopesChinadiarrhearotavirus vaccinesVP4VP7

Identifiers

PMID36004332
PMCPMC9393338

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.